Eupraxia Pharmaceuticals AI Stock Analysis
Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis
Eupraxia Pharmaceuticals
(NASDAQ:EPRX)
No summary available
Eupraxia Pharmaceuticals (EPRX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $783.37M
- Dividend Yield
- ―
- Average Volume (3M)
- 690.76K
- Price to Earnings (P/E)
- -7.8
- Beta (1Y)
- 1.27
- Revenue Growth
- ―
- EPS Growth
- -18.46%
- Country
- US
- Employees
- 49
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Eupraxia Pharmaceuticals Business Overview & Revenue Model
Company Description
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, target...
Eupraxia Pharmaceuticals Peers Comparison
Overall Rating
TSE:DRUG47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 47Neutral | CAD 325.38M | -11.29 | -12.56% | ― | ― | -117.77% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EPRX | Eupraxia Pharmaceuticals, Inc. | 8.15 | 1.78 | 27.94% | |
| TSE:DRUG | Bright Minds Biosciences Inc. | 32.75 | -48.08 | -59.48% | |
| TSE:MYND | Mynd Life Sciences Inc | 0.07 | 0.00 | 0.00% | |
| TSE:MBIO | Mindbio Therapeutics Corp. | 0.10 | -1.15 | -92.00% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
